Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

AIMS: The GLP1 agonist lixisenatide is glucagonostatic and reduces post‐prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D). METHODS: In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lix...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballav, Chitrabhanu, Dhere, Archana, Kennedy, Irene, Agbaje, Olorunsola F., White, Sarah, Franklin, Rachel, Hartmann, Bolette, Holst, Jens J., Holman, Rury R., Owen, Katharine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375047/
https://www.ncbi.nlm.nih.gov/pubmed/32704555
http://dx.doi.org/10.1002/edm2.130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375047/
https://www.ncbi.nlm.nih.gov/pubmed/32704555
http://dx.doi.org/10.1002/edm2.130

Ejemplares similares